Home > Insider Trading > Filing (0001179110-16-024699)

Filing Details

Accession Number:: 0001179110-16-024699
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-05-16 08:25:42
Reporting Period:: 2016-05-12

Filing Date:: 2016-05-16
Accepted Time:: 2016-05-16 08:25:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544227	Ovascience Inc.	OVAS	Pharmaceutical Preparations (2834)	451472564

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1551614	Michelle Dipp	C/O Ovascience, Inc. 9 Fourth Ave. Waltham MA 02451	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-05-12	14,200	$6.72	455,161	No	4	P	Indirect	By Longwood Fund III LP
Common Stock	Acquisiton	2016-05-12	5,600	$7.13	460,761	No	4	P	Indirect	By Longwood Fund III LP
Common Stock	Acquisiton	2016-05-13	16,295	$7.06	477,056	No	4	P	Indirect	By Longwood Fund III LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Longwood Fund III LP
No	4	P	Indirect	By Longwood Fund III LP
No	4	P	Indirect	By Longwood Fund III LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	971,921	Direct

Footnotes

This Form 4 reflects the purchase of an aggregate of 36,095 shares by the Longwood Fund III LP in the market. The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D. and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.99, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.00 to $7.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.62 to $7.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.